Is pharma in for a swarm of subpoenas? Are we running out of ideas in oncology? And can a drug possibly be worth $4 million a dose?

We discuss all that and more on the latest episode of “The Readout LOUD,” STAT’s biotech podcast. First, STAT’s Lev Facher joins us to recap the midterms, going over what the new Congress has in store for drug prices, victories for anti-pharma crusaders, and the end of former Celgene CEO Bob Hugin’s campaign for Senate. Then, on the eve of a major cancer conference, we’ll dig into how the seemingly bright future for combining immuno-oncology drugs has led to surprising disappointment. Finally, a new gene therapy from Novartis has showed dramatic effects on a rare and deadly disease. The company says it would be cost-effective with a $4 million price tag, and not everyone agrees.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • 4 Million $/mo ?

    Talk about high pricing!

    Would there be consideration for their parents if they were affected?

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy